SPHK1 and cancer: There is a strong drive for SphK2 inhibitors given that they appear to be more efficacious than SphK1 inhibitors in in vitro cancer cell line studies and cancer clinical trial studies, in particular the SphK2 inhibitor ABC294640 (Table 4).